Evofem Biosciences, Inc.
For the period ended Sep 30, 2025. Filed Nov 13, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 13, 2025
EVFM$0.48-23.4%Stored close · as of Aug 10, 2022
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations
(In thousands, except share and per share data)
| Three Months Ended September 30, | Nine Months Ended September 30, | |||
|---|---|---|---|---|
| 2025 | 2024 | 2025 | 2024 | |
| Product sales, net | $4,952 | $4,496 | $10,622 | $12,259 |
| Operating Expenses: | ||||
| Cost of goods sold | 905 | 869 | 2,025 | 2,322 |
| Gain on change in accounting estimates on contingent royalty liability (Note 7) | (1,933) | - | (1,933) | - |
| Amortization of intangible asset | 80 | 301 | 410 | 301 |
| Research and development, net | 470 | 332 | (3,819) | 1,196 |
| Selling and marketing | 2,391 | 2,382 | 7,616 | 6,970 |
| General and administrative | 2,088 | 3,052 | 6,296 | 8,143 |
| Total operating expenses | 4,001 | 6,936 | 10,595 | 18,932 |
| Income (loss) from operations | 951 | (2,440) | 27 | (6,673) |
| Other income (expense): | ||||
| Interest income | 3 | 3 | 13 | 13 |
| Other expense, net | (682) | (562) | (1,944) | (1,736) |
| Loss on issuance of financial instruments | - | - | - | (3,300) |
| Gain (loss) on debt extinguishment, net | - | (143) | - | 977 |
| Change in fair value of financial instruments | (1,845) | 769 | (490) | 4,896 |
| Total other income (expense), net | (2,524) | 67 | (2,421) | 850 |
| Loss before income tax benefit (expense) | (1,573) | (2,373) | (2,394) | (5,823) |
| Income tax benefit (expense) | 4 | 8 | (3) | - |
| Net loss | (1,569) | (2,365) | (2,397) | (5,823) |
| Convertible and redeemable preferred stockdeemed dividends | (111) | (5) | (115) | (99) |
| Net loss attributable to common stockholders | $(1,680) | $(2,370) | $(2,512) | $(5,922) |
| Net loss per share attributable to common stockholders, basic and diluted | $(0.01) | $(0.02) | $(0.02) | $(0.09) |
| Weighted-average shares used to compute net loss per share attributable to common shareholders, basic and diluted | 119,578,093 | 96,459,121 | 116,229,614 | 64,924,454 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.